Background: The landmark EXTREME trial established cisplatin, 5-fluorouracil and
cetuximab (PFE) as first-line chemotherapy (1L-ChT) for recurrent/metastatic head and
neck squamous cell carcinoma (R/M HNSCC). We were interested in outcome differences
of R/M HNSCC in 1L-ChT and factors influencing outcome in certain subgroups,
especially patients receiving PFE, and the value of PFE compared to other 1L-ChT
regimens to provide real world evidence (RWE).
Methods: For this retrospective monocentric study, 124 R/M HNSCC patients without
curative surgical or radiotherapy options receiving at least one cycle of 1L-ChT were
eligible. We analyzed their outcome using Kaplan-Meier plot and Cox regression to identify
predictors for prolonged survival.
Results: Subgroups benefiting significantly from PFE were patients suffering from an
index HNSCC outside the oropharynx. The PFE regimen proved to be superior to all other
1L-ChT regimens in clinical routine. Significant outcome differences between PFE
treatment within or outside controlled trials were not seen.
Conclusion: This retrospective analysis provides RWE for factors linked to improved
outcome. Subgroup analyses highlight the lasting value of PFE among the growing
spectrum of 1L-ChT. Importantly, fit smokers with high level alcohol consumption benefit
from PFE; considering the patient’s lifestyle factors, PFE should not be ignored in
decision-making.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84395 |
| Date | 30 March 2023 |
| Creators | Lübbers, Katharina, Pavlychenko, Mykola, Wald, Theresa, Wiegand, Susanne, Dietz, Andreas, Zebralla, Veit, Wichmann, Gunnar |
| Publisher | Frontiers Research Foundation |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 2234-943X, 715297 |
Page generated in 0.0051 seconds